$30.07
▲ +11.0% Today
as of Aug 5, 16:45 ET
Last 30 days
Recent Press Releases & News
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Q2 2026 -- GF Value Sees 57% Upside
Arcutis Biotherapeutics (ARQT) Stock Trades At A Discount To Sales But Fair Value Looks Tight
Arcutis Biotherapeutics (ARQT) Heads Into Earnings With Its ZORYVE Story Still Shaping Valuation
Overview
52-week range
$13
$32
91% of range
Avg surprise (last 3)
-105.8%
Avg reaction (last 2)
-1.9%
50% positive
Latest IV / EM
155%
EM ±25.8% · $30 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-0.09 | $-0.02 | -350.0% | +55.0% | +3.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.06 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.13 | $-0.18 | +27.8% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.20 | $-0.21 | +4.8% | — | -7.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.33 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.42 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.32 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.73 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-1.16 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | AMC | $0.09 | -$0.13 | +169.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $105M | — | $99M | $82M | $66M | — | $45M | $31M |
| Cost of revenue | $10M | — | $9M | $7M | $9M | — | $6M | $3M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-9M | — | $9M | $-15M | $-25M | — | $-39M | $-50M |
| Net income | $-11M | — | $7M | $-16M | $-25M | — | $-42M | $-52M |
| EPS (diluted) | $-0.09 | — | $0.06 | $-0.13 | $-0.20 | — | $-0.33 | $-0.42 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $35M | $43M | $47M | $73M | $53M | $71M | $135M | $84M |
| Inventory | $37M | $23M | $22M | $16M | $17M | $15M | $14M | $14M |
| Total current assets | $438M | $411M | $349M | $333M | $324M | $336M | $424M | $435M |
| Total assets | $460M | $433M | $371M | $352M | $344M | $349M | $437M | $445M |
| Long-term debt | $101M | $108M | $107M | $107M | $108M | $107M | $105M | $204M |
| Total liabilities | $270M | $243M | $213M | $213M | $201M | $191M | $281M | $258M |
| Total equity | $190M | $189M | $158M | $139M | $143M | $158M | $157M | $186M |